Osimertinib has been the standard treatment for patients with metastatic T790M-positive NSCLC that progressed from EGFR-TKI treatment based on the AURA3 clinical trial with an impressive PFS extension [10–12]. Here, EGFR is linked to non-small cell lung carcinoma.